Synairgen Plc (SNG):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Synairgen Plc (SNG) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10143)・商品コード:DATA904C10143
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:31
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Synairgen plc (Synairgen) is a drug discovery and development company, which focuses on the development of novel drugs for the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). Its pipeline portfolio includes inhaled interferon beta (IFN-ß/SNG001) for asthma in Phase II trial; and IFN-ß (SNG001) for COPD in Phase I trial. The company develops its drugs based on its BioBank platform technology. Its BioBank comprises blood, sputum, nasal lavage, biopsies, bronchial epithelial cells and fibroblasts from volunteers with asthma and COPD. The company uses these resources to develop in vitro and ex vivo models, which can be used for discovering novel drug targets. It discovers and develops the drug targets through early stages and out-licenses them to other pharmaceutical companies for further development and manufacturing. Synairgen is headquartered at Southampton, the UK.

Synairgen Plc (SNG) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Synairgen Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Synairgen Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Synairgen Plc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Pharmaxis Expands Agreement with Synairgen 10
Licensing Agreements 11
AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 11
Equity Offering 13
Synairgen to Raise USD3.7 Million in Private Placement of Shares 13
Synairgen Raises USD9 Million in Private Placement of Shares 15
Synairgen Announces Private Placement Of Shares For US$2.5 Million 17
Synairgen Completes Private Placement Of Shares For US$4 Million 18
Synairgen Plc – Key Competitors 19
Synairgen Plc – Key Employees 20
Synairgen Plc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Recent Developments 22
Financial Announcements 22
Sep 25, 2018: Synairgen: Interim results for the six months ended 30 June 2018 22
Mar 15, 2018: Synairgen: Preliminary statement of results for the year ended 31 December 2017 26
Sep 27, 2017: Synairgen: Interim results for the six months ended 30 June 2017 27
May 17, 2017: Synairgen Announces Preliminary statement of results for the year ended 31 December 2016 28
Product News 29
04/27/2017: Synairgen Provides Update On AZD9412 29
Mar 10, 2017: Synairgen: Additional Positive Data in Lung Fibrosis 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Synairgen Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Synairgen Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Synairgen Plc, Deals By Therapy Area, 2012 to YTD 2018 8
Synairgen Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Pharmaxis Expands Agreement with Synairgen 10
AstraZeneca Enters into Licensing Agreement with Synairgen for SNG001 11
Synairgen to Raise USD3.7 Million in Private Placement of Shares 13
Synairgen Raises USD9 Million in Private Placement of Shares 15
Synairgen Announces Private Placement Of Shares For US$2.5 Million 17
Synairgen Completes Private Placement Of Shares For US$4 Million 18
Synairgen Plc, Key Competitors 19
Synairgen Plc, Key Employees 20
Synairgen Plc, Subsidiaries 21

List of Figures
Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Synairgen Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Synairgen Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Synairgen Plc (SNG):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10143)販売に関する免責事項を必ずご確認ください。
★調査レポート[Synairgen Plc (SNG):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆